StockNews.com upgraded shares of Assertio (NASDAQ:ASRT - Free Report) from a hold rating to a buy rating in a report issued on Monday morning.
ASRT has been the topic of a number of other reports. Industrial Alliance Securities set a $1.75 price target on Assertio in a research note on Friday, March 14th. HC Wainwright cut their price objective on shares of Assertio from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Wednesday, March 19th.
Check Out Our Latest Analysis on ASRT
Assertio Trading Down 1.7 %
ASRT stock traded down $0.01 during midday trading on Monday, hitting $0.61. 295,436 shares of the company's stock were exchanged, compared to its average volume of 740,578. The business has a 50-day simple moving average of $0.72 and a two-hundred day simple moving average of $0.86. Assertio has a 1-year low of $0.51 and a 1-year high of $1.80. The company has a current ratio of 2.01, a quick ratio of 1.57 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $58.46 million, a PE ratio of -0.84, a P/E/G ratio of 3.25 and a beta of 0.56.
Institutional Trading of Assertio
A number of institutional investors have recently modified their holdings of ASRT. Captrust Financial Advisors acquired a new stake in Assertio in the third quarter valued at $26,000. Stifel Financial Corp acquired a new stake in shares of Assertio in the fourth quarter valued at about $27,000. Commonwealth Equity Services LLC acquired a new position in Assertio during the fourth quarter worth about $30,000. Sonora Investment Management Group LLC purchased a new position in Assertio in the fourth quarter valued at about $39,000. Finally, Wealthfront Advisers LLC acquired a new stake in shares of Assertio during the 4th quarter valued at approximately $53,000. 48.96% of the stock is currently owned by hedge funds and other institutional investors.
About Assertio
(
Get Free Report)
Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
Further Reading
Before you consider Assertio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assertio wasn't on the list.
While Assertio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
